Prescribing behaviour according to Dutch and European guidelines on the management of hypercholesterolaemia (1992-1999)

British Journal of Clinical Pharmacology

Volumn 61, Issue 5, 2006, Pages 592-600

  Mantel Teeuwisse, Aukje K ^a,b   Klungel, Olaf H ^a   Hofman, Albert ^b   Verschuren, W M Monique ^c   Trienekens, Paul H ^d   Porsius, Arijan J ^a   Stricker, Bruno H Ch ^b   De Boer, Anthonius ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d STAR (Stichting Trombosedienst and Artsenlaboratorium Rijnmond) Laboratory   (Netherlands)

Author keywords

Guideline adherence; Hydroxymethylglutaryl CoA reductase inhibitors; Hypercholesterolaemia

Indexed keywords

ANTIHYPERTENSIVE AGENT; CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; STATINE DERIVATIVE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; EUROPE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; NETHERLANDS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CHI-SQUARE DISTRIBUTION; CHOLESTEROL; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; EUROPE; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; NETHERLANDS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; STATISTICS, NONPARAMETRIC;

EID: 33646246995     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02634.x     Document Type: Article

References (26)

1. LaRosa JC He J Vupputuri S Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials JAMA 1999 282 2340 6
2. Mitka M Expanding statin use to help more at-risk patients is causing financial heartburn JAMA 2003 290 2243 5
3. Stichting Farmaceutische Kengetallen. Data en feiten 2003 [in Dutch]. Den Haag 2003
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 1994 344 1383 9
5. Shepherd J Cobbe SM Ford I Isles CG Lorimer AR MacFarlane PW McKillop JH Packard CJ Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N Engl J Med 1995 333 1301 7
6. Sacks FM Pfeffer MA Moye LA Rouleau JL Rutherford JD Cole TG Brown L Warnica JW Arnold JMO Wun CC Davis BR Braunwald E The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 1996 335 1001 9
7. The Long-Term Intervention with Pravastatin in Ischaemic Disease Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 1998 339 1349 57
8. Downs JR Clearfield M Weis S Whitney E Shapiro DR Beere PA Langendorfer A Stein EA Kruyer W Gotto AM Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 1998 279 1615 22
9. Heart Protection Study Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial Lancet 2002 360 7 22
10. Sever PS Dahlof B Poulter NR Wedel H Beevers G Caulfield M Collins R Kjeldsen SE Kristinsson A McInnes GT Mehlsen J Nieminen M O'Brien E Östergren J Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 2003 361 1149 58
11. Jukema JW Simoons ML Treatment and prevention of coronary heart disease by lowering serum cholesterol levels; from the pioneer work of C.D. de Langen to the third 'Dutch Consensus on Cholesterol' Acta Cardiol 1999 54 163 8
12. Thomas S Van der Weijden T Van Drenth BB Haverkort AFM Hooi JD Van der Laan JD NHG-Standaard Cholesterol [In Dutch.] Huisarts Wet 1999 42 406 17
13. Anonymous. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention Eur Heart J 1998 19 1434 503
14. De Backer G Ambrosioni E Borch-Johnsen K Brotons C Cifkova R Dallongeville J Ebrahim S Faergeman O Graham I Mancia G Manger Cats V Orth-Gomér K Perk J Pyörälä K Rodicio JL Sans S Sansoy V Sechtem U Silber S Thomsen T Wood D European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice Eur Heart J 2003 24 1601 10
15. Hofman A Grobbee DE de Jong PT van den Ouweland FA Determinants of disease and disability in the elderly: the Rotterdam Elderly Study Eur J Epidemiol 1991 7 403 22
16. Maitland-van der Zee AH Klungel OH Stricker BH Van der Kuip DA Witteman JC Hofman A Leufkens HGM de Boer A Repeated nitrate prescriptions as a potential marker for angina pectoris. A comparison with medical information from the Rotterdam Study Pharm World Sci 2003 25 70 2
17. Anderson KM Odell PM Wilson PWF Kannel WB Cardiovascular disease risk profiles Am Heart J 1990 121 293 8
18. Erkelens DW Revision of consensus cholesterol [In Dutch.] Ned Tijdschr Geneeskd 1991 135 2337 40
19. Lansberg PJ Tuzgol S van de Ree MA Defesche JC Kastelein JJ Higher prevalence of familiar hypercholesterolemia than expected in adult patients of four family practices in Netherlands [In Dutch.] Ned Tijdschr Geneeskd 2000 144 1437 40
20. Shepherd J Blauw GJ Murphy MB Bollen EL Buckley BM Cobbe SM Ford I Gaw A Hyland M Jukema JW Kamper AM Macfarlane PW Meinders AE Norrie J Packard CJ Perry IJ Stott DJ Sweeney BJ Twomey C Westendorp RGJ Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 2002 360 1623 30
21. Warburton RN What do we gain from the sixth coronary heart disease drug? BMJ 2003 327 1237 8
22. Mantel-Teeuwisse AK Verschuren WMM Klungel OH Kromhout D Lindemans AD Avorn J Porsius AJ de Boer A Undertreatment of hypercholesterolemia: a population-based study Br J Clin Pharmacol 2003 55 389 97
23. Van Wyk JT Picelli G Dieleman JP Mozaffari E Kramarz P van Wijk MAM van der Lei J Sturkenboom MCJM Management of hypertension and hypercholesterolaemia in primary care in the Netherlands Curr Med Res Opin 2005 21 839 48
24. Cabana MD Rand CS Powe NR Wu AW Wilson MH Abboud PA Rubin HR Why don't physicians follow clinical practice guidelines? A framework for improvement JAMA 1999 282 1458 65
25. Mantel-Teeuwisse AK Klungel OH Verschuren WM Porsius AJ de Boer A Time trends in lipid lowering drug use in The Netherlands. Has the backlog of candidates for treatment been eliminated? Br J Clin Pharmacol 2002 53 379 85
26. Lemaitre RN Furberg CD Newman AB Hulley SB Gordon DJ Gottdiener JS McDonald RH Psaty BM Time trends in the use of cholesterol-lowering agents in older adults: the Cardiovascular Health Study Arch Intern Med 1998 158 1761 8